Calculateur du temps de doublement volumique d’un nodule pulmonaire

État

clinical-review-pending

Version de la méthode

Zhou 2016 pulmonary-nodule volume-only positive-growth arithmetic v1: VDT days = ln(2) × elapsed interval days / ln(later CT-derived whole-nodule volume / initial CT-derived whole-nodule volume); volume accepts mm³, mL, or cm³ with 1 mL = 1 cm³ = 1000 mm³; later volume greater than initial returns a raw positive finite VDT, equal volumes return an explicit stable-volume state, and lower later volume returns an explicit decreasing-volume state without a numeric VDT

Population

People for whom applicability of the source pulmonary-nodule and paired-CT volumetry context is independently established, with a selected opacity confirmed to be no larger than 3 cm. Both positive volumes must measure the same physical nodule and the same whole-nodule volumetric target on an initial and later CT, using comparable acquisition and reconstruction settings, the same volumetry software and release, the same segmentation method and measurement definition, verified units, and an explicit positive elapsed interval in days.

Limites et exclusions

A lesion larger than 3 cm, pediatric use, or extrapolation beyond the source pulmonary-nodule and paired-CT context without independently established applicability. · Diameter-derived, area-derived, mass-derived, density-derived, solid-component, or mixed measurement methods; another lesion; non-comparable CT acquisition or reconstruction; different software, release, segmentation method, or volumetric definition; inferred units; or an absent or nonpositive scan interval. · Treating stable whole-nodule volume as absence of clinically important change, especially for ground-glass or part-solid nodules where attenuation or a solid component may change; treating an arithmetic volume change as proof of biological growth; or assuming constant exponential growth represents actual biology. · Any benignity or malignancy category, risk band, action threshold, diagnosis, prognosis, reassurance, surveillance interval, biopsy decision, monitoring plan, treatment, management recommendation, or other clinical decision.

• https://pmc.ncbi.nlm.nih.gov/articles/PMC5973458/
• https://doi.org/10.3779/j.issn.1009-3419.2016.12.12
• https://pmc.ncbi.nlm.nih.gov/articles/PMC10587693/
• https://pubmed.ncbi.nlm.nih.gov/28650738/
• https://doi.org/10.1148/radiol.2017162894
• https://pmc.ncbi.nlm.nih.gov/articles/PMC5905770/

Outil importé de la bibliothèque PharmaTek de MDose. Aucune date de révision clinique indépendante n’est documentée dans cette version.

Bibliothèque source

PharmaTek · MDose

Version importée

4b66536936ed

État de publication

Révision clinique en cours